Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Medicina (B Aires). 2000 Jan 1; 60 Suppl 2: 41-7.
KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.
Cancer Res. 2006 Sep 15; 66 (18): 9134-42.